The efficacy of two immunostimulants against Flavobacterium columnare infection in juvenile rainbow trout (Oncorhynchus mykiss).
Bacterium Flavobacterium columnare is the causative agent of columnaris disease in many wild and farmed fish species. Immunostimulants are used with success in aquaculture against many pathogens, but the ability to improve innate resistance to columnaris disease has not been studied. Fingerling rainbow trout were treated with two immunostimulants, yeast beta-glucan and beta-hydroxy-beta-methylbutyrate (HMB). Selected innate immune function parameters, the production of reactive oxygen species (ROS) by whole blood and by isolated head kidney leukocytes, plasma lysozyme activity and complement bacteriolytic activity, were determined to assess the immune status of fish. The fish were then bath challenged with virulent F. columnare bacteria, and the mortality of fish was recorded. Given orally both stimulants raised the levels of immune function parameters, but did not improve survival in challenge at any concentration of the stimulants used. Intra peritoneal injection of beta-glucan increased parameter values several fold, but no beneficial effect of injected glucan on survival was noted. As a control, antibiotic medication administered prior to and during the challenge infection prevented the mortality. Innate immune mechanisms, even when induced to high levels with immunostimulants, as evidenced here, were not able to increase resistance against F. columnare. This may be connected to the external character of the infection. The results from the treatments with beta-glucan and HMB suggest that there is little prospect of preventing columnaris disease by means of immunostimulants in early life stage of rainbow trout. However, the efficacy of other immune stimulants remains open.
Kunttu
Heidi M T
HM
Department of Biological and Environmental Science, University of Jyväskylä, Finland.
Valtonen
E Tellervo
ET
Suomalainen
Lotta-Riina
LR
Vielma
Jouni
J
Jokinen
Ilmari E
IE
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D017756:Aquaculture; D003165:Complement System Proteins / Q000276:immunology; D005393:Fish Diseases / Q000276:immunology / Q000382:microbiology / Q000628:therapy*; D045826:Flavobacteriaceae Infections / Q000276:immunology / Q000382:microbiology / Q000628:therapy / Q000662:veterinary*; D005417:Flavobacterium / Q000276:immunology*; D053208:Kaplan-Meier Estimate; D009113:Muramidase / Q000097:blood; D017686:Oncorhynchus mykiss; D017382:Reactive Oxygen Species / Q000097:blood / Q000276:immunology; D014631:Valerates / Q000627:therapeutic use*; D047071:beta-Glucans / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D017382:Reactive Oxygen Species; D014631:Valerates; D047071:beta-Glucans; C004961:beta-hydroxyisovaleric acid; D003165:Complement System Proteins; D009113:Muramidase